{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-089436","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-08-03T11:00:23+00:00","discovered_at":"2026-08-03T11:05:00.299865+00:00","generated_at":"2026-08-03T11:05:43.493378+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioXcel defers $9M payment to Aug 31, cuts liquidity covenant to $6.25M","bullets":["Deferred $9,016,914.47 principal+interest due June 30 to Aug 31, 2026.","Minimum liquidity covenant reduced from $7.5M to $6.25M.","Must enter definitive agreements for acceptable transaction by Aug 10, 2026.","Prohibited from modifying compensation arrangements through Aug 31, 2026.","Oaktree lenders agreed to these amendments."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-089436","json":"https://secwatch.observer/filing/0001104659-26-089436.json","markdown":"https://secwatch.observer/filing/0001104659-26-089436.md","text":"https://secwatch.observer/filing/0001104659-26-089436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926089436/0001104659-26-089436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926089436/tm2622012d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:05:43.493378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}